Rsf-1 overexpression serves as a prognostic marker in human hepatocellular carcinoma

Tumor Biology

Volumn 35, Issue 8, 2014, Pages 7595-7601

  Xie, Chengyao ^a   Fu, Lin ^a   Xie, Lingling ^a   Liu, Nan ^a   Li, Qingchang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Prognosis; Proliferation; Rsf 1

Indexed keywords

CYCLIN D1; CYCLIN E; ONCOPROTEIN; RSF 1 PROTEIN; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; NUCLEAR PROTEIN; RSF1 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC TRANSFECTION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MTT ASSAY; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; WESTERN BLOTTING; AGED; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENETICS; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYCLIN D1; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84920964485     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2008-8     Document Type: Article

References (35)

1. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48(4):1312–27.
2. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S206–14.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
4. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg. 2002;235(3):373–82.
5. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology. 2001;34(4 Pt 1):707–13.
6. Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J, et al. Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. Clin Cancer Res. 2011;17(1):46–55.
7. Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010;136(2):275–81.
8. Zhao ZK, Dong P, Gu J, Chen L, Zhuang M, Lu WJ, et al. Overexpression of LSD1 in hepatocellular carcinoma: a latent target for the diagnosis and therapy of hepatoma. Tumour Biol. 2013;34(1):173–80.
9. Davidson B, Trope CG, Wang TL, Shih Ie M. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival. Gynecol Oncol. 2006;103(3):814–9.
10. Shih Ie M, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, et al. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005;102(39):14004–9.
11. Huang X, Gollin SM, Raja S, Godfrey TE. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A. 2002;99(17):11369–74.
12. Li Q, Dong Q, Wang E. Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem Biophys Res Commun. 420(1):6–10.
13. Liu S, Dong Q, Wang E. Rsf-1 overexpression correlates with poor prognosis and cell proliferation in colon cancer. Tumour Biol. 33(5):1485–91.
14. Sheu JJ, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, et al. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development. J Pathol. 2013;229(4):559–68.
15. Zhang YJ, Jiang W, Chen CJ, Lee CS, Kahn SM, Santella RM, et al. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1993;196(2):1010–6.
16. Sakakura C, Hagiwara A, Taniguchi H, Yamaguchi T, Yamagishi H, Takahashi T, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer. 1999;80(12):2034–9.
17. Wong N, Lai P, Pang E, Fung LF, Sheng Z, Wong V, et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res. 2000;6(10):4000–9.
18. Davidson B, Wang TL, Shih Ie M, Berner A. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Hum Pathol. 2008;39(4):616–22.
19. Wahafu W, He ZS, Zhang XY, Zhang CJ, Yao K, Hao H, et al. The nucleosome binding protein NSBP1 is highly expressed in human bladder cancer and promotes the proliferation and invasion of bladder cancer cells. Tumour Biol. 2011;32(5):931–9.
20. Davis PK, Brackmann RK. Chromatin remodeling and cancer. Cancer Biol Ther. 2003;2(1):22–9.
21. Klochendler-Yeivin A, Muchardt C, Yaniv M. SWI/SNF chromatin remodeling and cancer. Curr Opin Genet Dev. 2002;12(1):73–9.
22. Wolffe AP. Chromatin remodeling: why it is important in cancer. Oncogene. 2001;20(24):2988–90.
23. Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet. 2006;14(4):381–3.
24. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol. 2006;100(2):264–70.
25. Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 2007;26(49):6997–7005.
26. Cheng CK, Chow LW, Loo WT, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res. 2005;65(19):8646–54.
27. Rosen A, Sevelda P, Klein M, Dobianer K, Hruza C, Czerwenka K, et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer. 1993;67(5):1122–5.
28. Seki A, Yoshinouchi M, Seki N, Kodama J, Miyagi Y, Kudo T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification in epithelial ovarian cancer. Int J Oncol. 2000;17(1):103–6.
29. Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, et al. Overexpression of a chromatin remodeling factor, RSF-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol. 178(5):2407–15.
30. Endo M, Yasui K, Zen Y, Gen Y, Zen K, Tsuji K, et al. Alterations of the SWI/SNF chromatin remodelling subunit-BRG1 and BRM in hepatocellular carcinoma. Liver Int. 2013;33(1):105–17.
31. Zhong R, Liu L, Tian Y, Wang Y, Tian J, Zhu BB, et al. Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis. Sci Rep. 2014;4:4147.
32. Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YT, et al. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem. 285(49):38260–9.
33. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL, et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res. 2009;69(4):1407–15.
34. Mazumder S, DuPree EL, Almasan A. A dual role of cyclin E in cell proliferation and apoptosis may provide a target for cancer therapy. Curr Cancer Drug Targets. 2004;4(1):65–75.
35. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103(1):127–40.